How to manage patients with lupus nephritis

Bailliere's Best Practice and Research in Clinical Rheumatology

Volumn 16, Issue 2, 2002, Pages 195-210

  Esdaile, John M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

Experimental treatment; Lupus nephritis; Renal biopsy; Therapy

Indexed keywords

ABETIMUS; ACROLEIN; ANTICOAGULANT AGENT; AZATHIOPRINE; BINDARIT; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; FLAXSEED OIL; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MESNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; ONDANSETRON; PLACEBO; PREDNISOLONE; PREDNISONE; SEPHAROSE; STAPHYLOCOCCUS PROTEIN A; UNCLASSIFIED DRUG; PLANT EXTRACT; RECOMBINANT DNA;

AGRANULOCYTOSIS; ALOPECIA; AMENORRHEA; ANTIPHOSPHOLIPID SYNDROME; APLASTIC ANEMIA; ARTHRITIS; BACTERIAL INFECTION; BILIARY TRACT FIBROSIS; BLADDER CANCER; CHRONICITY; CLINICAL TRIAL; COMPARATIVE STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG CARCINOGENICITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG PREFERENCE; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNOADSORPTION; INFECTION; INFERTILITY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; LABORATORY TEST; LEUKOPENIA; LIBIDO DISORDER; LONG TERM CARE; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MESANGIUM; META ANALYSIS; MONOTHERAPY; MORTALITY; MULTIPLE ORGAN FAILURE; MYELOPROLIFERATIVE DISORDER; NAUSEA AND VOMITING; NEPHRITIS; NEPHROTOXICITY; OUTCOMES RESEARCH; OVARY INSUFFICIENCY; PATIENT CARE; PATIENT MONITORING; PLASMAPHERESIS; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; PROLIFERATIVE GLOMERULONEPHRITIS; REVIEW; SIDE EFFECT; SKIN CANCER; TERATOGENICITY; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VULVA CARCINOMA; WORLD HEALTH ORGANIZATION; CLINICAL PRACTICE; INTERNATIONAL CLASSIFICATION OF DISEASES; SPERMATOZOON COUNT; SYSTEMATIC REVIEW;

HUMANS; LUPUS NEPHRITIS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 0036527028     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2001.0221     Document Type: Review

References (60)

1. Le Thi Huong D, Papo T, Beaufils H et al. Renal involvement in systemic lupus erythematosus: As study of 180 patients from a single center. Medicine 1999; 78: 148-166 (Baltimore).
2. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period: A multicenter prospective study of 1000 patients. Medicine 1999; 78: 167-175 (Baltimore).
3. Neumann K, Wallace DJ, Azen C et al. Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single centre. Seminars in Arthritis and Rheumatism 1995; 25: 47-55.
4. Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome: Clinical and laboratory features of 50 patients. Medicine 1998; 77: 195-207 (Baltimore)
5. Østensen M & Villager PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus 2001; 10: 135-139.
6. Gladman DD, Urowitz MB, Esdaile JM et al. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis & Rheumatism 1999; 42: 1785-1796.
7. Levey AS, Lan S-P, Corwin HL et al. Progression and remission of renal disease in the lupus nephritis collaborative study: Results of treatment with prednisone and short-term oral cyclophosphamide. Annals of Internal Medicine 1992; 116: 114-123.
8. Esdaile JM, Joseph L, MacKenzie T et al. The benefit of early treatment with immunosuppressive agents in lupus nephritis. Journal of Rheumatology 1994; 21: 2046-2051.
9. Ciruelo E, De La Cruz J, López I & Gómez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis & Rheumatism 1996; 39: 2028-2034.
10. Esdaile JM. Current role of renal biopsy in patients with SLE. Baillière's Clinical Rheumatology 1998; 12: 433-448.
11. Austin HA III, Boumpas DT, Vaughan EM & Balow JE. High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients. Nephrology, Dialysis and Transplantation 1995; 10: 1620-1628.
12. Dooley MA, Hogan S, Jennette C et al. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Kidney International 1997; 51: 1188-1195.
13. Font J, Ramos-Casals M, Cervera R et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. Quarterly Journal of Medicine 2001; 94: 19-26.
14. Ward MM & Studenski S. Clinical prognostic factors in lupus nephritis: The importance of hypertension and smoking. Archives of Internal Medicine 2082-2088.
15. Wallace DJ, Podell TE, Weiner JM et al. Lupus nephritis: Experience with 230 patients in a private practice from 1950 to 1980. American Journal of Medicine 1982; 72: 209-220.
16. Esdaile JM, Levinton C, Federgreen W et al. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature. Quarterly Journal of Medicine 1989; 72: 779-833.
17. Esdaile JM, Abrahamowicz M, MacKenzie T et al. The time-dependence of long-term prediction in lupus nephritis. Arthritis & Rheumatism 1994; 37: 359-368.
18. Esdaile JM, Abrahamowicz M & Grodzicky T. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis & Rheumatism 2001; 44: 2331-2337.
19. Ward MM. Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis. American Journal of Kidney Disease 2000; 36: 516-525.
20. Fraenkel L, MacKenzie T & Joseph L. Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. Journal of Rheumatology 1994; 21: 2052-2057.
21. Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome in severe lupus nephritis. American Journal of Kidney Disease 2000; 35: 904-914.
22. Schwartz MM, Kawala KS, Corwin HL & Lewis EJ. The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney International 1987; 32: 274-279.
23. Sloan RP, Korbet SM, Schwartz MM & Brook RZ. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Journal of the American Society of Nephrology 1996; 7: 299-305.
24. Najafi CC, Korbet SM, Lewis EJ et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus nephritis. Kidney International 2001; 59: 2156-2163.
25. Esdaile JM, Joseph L, MacKenzie T et al. The pathogenesis and prognosis of lupus nephritis: Information from repeat renal biopsy. Seminars in Arthritis and Rheumatism 1993; 23: 135-148.
26. Balow JE, Austin HA III, Muenz LR et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. New England Journal of Medicine 1984; 311: 491-495.
27. Goulet J-R, MacKenzie T, Levinton C et al. The longterm prognosis of lupus nephritis: The impact of disease activity. Journal of Rheumatology 1993; 20: 59-65.
28. Moroni G, Pasquali S, Quaglini S et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. American Journal of Kidney Disease 1999; 34: 530-539.
29. Schwartz MM. The holy grail: Pathological indices in lupus nephritis (editorial). Kidney International 2000; 58: 1354-1355.
30. Hill GS, Delahousse M, Nochy D et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney International 2000; 58: 1160-1173.
31. Bansal VK & Beto JA. Treatment of lupus nephritis: A meta-analysis of clinical trials. American Journal of Kidney Disease 1997; 29: 193-199.
32. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Annals of Internal Medicine 2001; 135: 296-298.
33. Pryor BD, Bologna SG & Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis & Rheumatism 1996; 39: 1475-1482.
34. Boumpas DT, Austin HA III, Vaughan EM et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Annals of Internal Medicine 1993; 119: 366-369.
35. Mok CC, Lau CS & Wong RWS. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis & Rheumatism 1998; 41: 831-837.
36. Radis CD, Kahl LE, Baker GL et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis & Rheumatism 1995; 38: 1120-1127.
37. Rahman P, Humphrey-Murto S, Gladman DD & Urowitz MB. Cytotoxic therapy in systemic lupus erythematosus: Experience from a single center. Medicine (Baltimore) 1997; 76: 432-437.
38. Nossent HC & Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39: 969-974.
39. Mok CC, Ho CTK, Siu YP et al. Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens. American Journal of Kidney Disease 2001; 38: 256-264.
40. Gordon C, Dostal C, Petera P et al. EULAR trial of pulse cyclophosphamide versus continuous cyclophosphamide followed by azathioprine in lupus nephritis. Arthritis & Rheumatism 1999; 42: S167 (abstract)
41. Tam LS, Li EK, Leung CB et al. Long-term treatment of lupus nephritis with cyclosporin A. Quarterly Journal of Medicine 1998; 91: 573-580.
42. Halevy D & Radhakrishnan J. Cyclosporin treatment of glomerular diseases. Expert Opinion on Investigational Drugs 2000; 9: 1053-1063.
43. Cross J & Jayne D. Mycophenolate mofetil in lupus nephritis (editorial). Lupus 2000; 9: 647-650.
44. Chan TM, Li FK, Tang CSO et al: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. New England Journal of Medicine 2000; 343: 1156-1162.
45. Falk RJ. Treatment of lupus nephritis - A work in progress (editorial). New England Journal of Medicine 2000; 343: 1182-1183.
46. Lewis EJ, Hunsicker LG, Lan S-P et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. New England Journal of Medicine 1992; 326: 1373-1379.
47. Euler HH, Schroeder JO, Harten P et al. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis & Rheumatism 1994; 37: 1784-1794.
48. Aringer M, Smolen JS & Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis & Rheumatism 1998; 41: 414-420.
49. Wallace DJ, Goldfinger D, Paepkowitz SH et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. Journal of Clinical Apheresis 1998; 13: 163-166.
50. Braun N, Erley C, Klein R et al. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrology, Dialysis and Transplantation 2000; 15: 1367-1372.
51. Rauova L, Lukac J, Levy Y, Rovensky J & Shoenfeld Y. High-dose intravenous immunoglobulins for lupus nephritis - A salvage immunomodulation. Lupus 2001; 10: 209-213.
52. Kazatchkine MD & Kaveri SV. Advances in immunology: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New England Journal of Medicine 2001; 345: 747-755.
53. Boletis JN, Iaonnidis JPA, Boki KA & Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999; 354: 569-570.
54. Wallace DJ. Clinical and pharmacological experience with LJP-394. Exp Opin Invest Drugs 2001; 10: 111-117.
55. Brodsky RA, Petri M, Smith BD et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory severe autoimmune disease. Annals of Internal Medicine 1998; 129: 1031-1035.
56. Traynor AE, Schroeder J, Rosa RM et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study. Lancet 2000; 356: 701-707.
57. Boumpas DT, Tassiulas IO, Fleisher TA et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clinical Nephrology 1999; 52: 67-75.
58. Davis JC Jr, Austin H 3rd, Boumpas D et al. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis & Rheumatism 1998; 41: 335-343.
59. Zimmerman R, Radhakrishnan J, Valeri A & Appel G. Advances in the treatment of lupus nephritis. Annual Review of Medicine 2001; 52: 63-78.
60. Chan TM, Li FK, Hao WK et al. Treatment of lupus membranous nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999; 8: 545-551.